9.3 C
New York
Thursday, March 28, 2024

CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified

Courtesy of Benzinga.

A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes’ drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes’ CEO nor the FDA have made any statement indicating if the drug will be approved.


For more Benzinga, visit Benzinga Professional Service, Value Investor, and Stocks Under $5.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,452FansLike
396,312FollowersFollow
2,280SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x